Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascelia Pharma ABOSTO:ACE +2.02%17 Net Cash per Share is kr0.21 as of Jun. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 763 Biotechnology companies, Ascelia Pharma AB ranks better than 66.71% on this metric.
Ascelia Pharma AB (OSTO:ACE) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Ascelia Pharma AB Net Cash per Share Related Terms
Ascelia Pharma AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Ascelia Pharma AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ACE vs VRTX, REGN, MRNA: Net Cash per Share Comparison
For the Biotechnology subindustry, Ascelia Pharma AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascelia Pharma AB Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Ascelia Pharma AB's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Ascelia Pharma AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascelia Pharma AB (OSTO:ACE) has a Net Cash per Share of kr0.21 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #254 out of 763 companies in the Biotechnology industry, placing it in the top 33.3%.
Is Ascelia Pharma AB's Net Cash per Share too high?
Ascelia Pharma AB's current Net Cash per Share is kr0.21. Based on the distribution chart, Ascelia Pharma AB ranks #254 out of 763 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascelia Pharma AB has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #254 out of 763 companies for Net Cash per Share. This puts Ascelia Pharma AB in the upper half of its industry. The industry median Net Cash per Share is 5.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.14, based on 763 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Ascelia Pharma AB and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascelia Pharma AB's current Net Cash per Share is kr0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Net Cash per Share of kr0.21. The current Net Cash per Share is kr0.21. Ascelia Pharma AB's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Net Cash per Share is kr0.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
17GF Score
Get the complete analysis for OSTO:ACE
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACE has been successfully added to your 
